Centre Hospitalier de l'Université de Montréal
Therapeutic targeting of adenosine in chronic lymphocytic leukemia
We want to investigate a new approach for treatment of chronic lymphocytic leukemia (CLL). We have shown that blocking adenosine makes the immune system better at destroying many cancer cells. We will use a mouse model of CLL and test the effect of blocking adenosine alone or in combination with other treatments. In addition we will see if CLL patients that fail treatment have a lot of adenosine.
B cell lymphoid neoplasms, such as chronic lymphocytic leukemia (CLL), are very common and often incurable diseases, despite recent introduction of targeted therapies. For patients in whom currently available treatments fail to control their disease, the identification of novel therapeutic targets may prove beneficial. These tumours are often associated with immunosuppression, induced either directly by the cancer cells themselves, or as a consequence of the expansion of distinct suppressive and immunoregulatory cell populations, such as Treg.